Biotech | November 20, 2021
Novo Nordisk to acquire Dicerna Pharmaceuticals for US $ 3.3 bn
Dicerna develops RNAi-based therapies to selectively silence genes that cause or contribute to disease
Dicerna develops RNAi-based therapies to selectively silence genes that cause or contribute to disease
Incidences of Non-alcoholic Fatty Liver Disease (NAFLD) have been rising exponentially worldwide and are associated with co-morbidities including obesity, diabetes, hypertension and metabolic disorders
The listings aim to address global health priorities, identifying the medicines that provide the greatest benefits, and which should be available and affordable for all
Nipah virus (NiV) is an emerging zoonotic disease that causes severe disease in humans. Signs and symptoms range from asymptomatic to acute respiratory infection and fatal encephalitis
India’s dependency on China for pharma intermediates can change if there is a proper coordination between educational institutes, research institutes and pharma manufacturers
The TWYMEEG approval is supported by numerous preclinical and clinical studies, including the Phase 3 TIMES (Trials of IMeglimin for Efficacy and Safety) program managed jointly by both the companies
Hetero is one of India’s leading generic pharmaceutical companies and the world’s largest producer of anti-retroviral drugs for the treatment of HIV/AIDS
PegIFN in COVID19 has several add-on advantages compared to other anti-viral agents
Subscribe To Our Newsletter & Stay Updated
